Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial - Summary - MDSpire
Advertisement
Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial
To assess the efficacy of once daily oral zasocitinib 15 mg or 30 mg in patients with moderate-to-severe plaque psoriasis through post hoc analyses of a phase IIb trial, specifically focusing on skin clearance and quality of life improvements.
Key Findings:
Zasocitinib 15 mg and 30 mg resulted in significant improvements in PASI scores compared to placebo at week 12, with 46%, 33%, and 52% of patients on 30 mg achieving PASI 90, PASI 100, and PGA 0/1 respectively.
Improvements in PASI scores were associated with better quality of life as measured by DLQI.
Interpretation:
Zasocitinib demonstrates early and clinically meaningful efficacy in skin clearance for patients with moderate-to-severe plaque psoriasis, with a favorable safety profile.
Limitations:
Post hoc analyses may introduce bias and limit the generalizability of findings; the lack of multiplicity adjustment may lead to inflated type I error rates.
Conclusion:
Zasocitinib is a promising oral treatment option for moderate-to-severe plaque psoriasis, showing significant efficacy in skin clearance and quality of life improvements, addressing an unmet need in psoriasis treatment.
by Nada Elbuluk, April W. Armstrong, Ronald Vender, Tina Bhutani, Lawrence Green, Laura K. Ferris, Vivian Laquer, Angela Moore, Jamie Weisman, Wenwen Zhang, Warren Winkelman, Melinda J. Gooderham
